Evidence map›Paper›PMID 27628967›Full record

ArticlePsychological medicine2016

Salience attribution and its relationship to cannabis-induced psychotic symptoms.

M A P Bloomfield, E Mouchlianitis, C J A Morgan, T P Freeman, H V Curran, J P Roiser, O D Howes

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychological medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

M A P BloomfieldPsychiatric Imaging Group,MRC Clinical Sciences Centre, Institute of Clinical Sciences, Hammersmith Hospital, Imperial College London,Du Cane Road,London W12 0NN,UK.
E MouchlianitisPsychiatric Imaging Group,MRC Clinical Sciences Centre, Institute of Clinical Sciences, Hammersmith Hospital, Imperial College London,Du Cane Road,London W12 0NN,UK.
C J A MorganClinical Psychopharmacology Unit,Research Department of Clinical,Educational and Health Psychology,University College London,4th Floor,1-19 Torrington Place,London WC1E 7HB,UK.
T P FreemanClinical Psychopharmacology Unit,Research Department of Clinical,Educational and Health Psychology,University College London,4th Floor,1-19 Torrington Place,London WC1E 7HB,UK.
H V CurranClinical Psychopharmacology Unit,Research Department of Clinical,Educational and Health Psychology,University College London,4th Floor,1-19 Torrington Place,London WC1E 7HB,UK.
J P RoiserInstitute of Cognitive Neuroscience,University College London,17 Queen Square,London WC1N 3AR,UK.
O D HowesPsychiatric Imaging Group,MRC Clinical Sciences Centre, Institute of Clinical Sciences, Hammersmith Hospital, Imperial College London,Du Cane Road,London W12 0NN,UK.
Hammersmith Hospital · GBUniversity College London · GBKing's College London · GBNational Hospital for Neurology and Neurosurgery · GBSinger (United States) · US

Funding

Department of HealthMedical Research Council G0700995Medical Research Council G0800268Medical Research Council MC-A656-5QD30Medical Research Council MC_U120097115Medical Research Council MR/K015524/1Medical Research Council MR/L023032/1
6 · The paper itself

Abstract

backgroundCannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.

methodWe tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography.

resultsThere was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04).

conclusionsAberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.

Indexed as

AdultBrainCannabisCase-Control StudiesDihydroxyphenylalanineDopamineFemaleHumansMaleMarijuana AbuseNeostriatumPositron-Emission TomographyPsychoses, Substance-InducedRadiopharmaceuticalsRewardYoung AdultDihydroxyphenylalanineDopaminefluorodopa F 18RadiopharmaceuticalsAddictioncannabisdopaminepsychosissalience

Identifiers

PMID27628967
PMCPMC5122315
OpenAlexW2519731368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.